N/A
Completed N=17
Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy
Source: ClinicalTrials.gov NCT01165775 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Sep 2016
Primary outcomePrimary: Percentage Time Spent Above Glucose Thresholds (>110;>144;>180) 24-48 Hours Post Betamethasone Treatment — 73; 79; 40; 58 percentage time
Summary
We hope to clarify how betamethasone affects glucose levels in the mother in the days after receiving the drug. This understanding will hopefully allow us to better anticipate the risk of maternal hyperglycemia and therefore establish more appropriate monitoring of maternal glucose to prevent maternal and neonatal complications of hyperglycemia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Time Spent Above Glucose Thresholds (>110;>144;>180) 24-48 Hours Post Betamethasone Treatment |
73; 79; 40; 58; 17; 24 | — |
| SECONDARY Neonatal Hypoglycemia |
2; 2; 0; 2; 4; 5 | 0.2155 |
Eligibility Criteria
Inclusion Criteria:- 18 years of age or older
- Receiving betamethasone as part of routine clinical care.
- Pregnancy between 23+5 and 35+0 weeks Exclusion Criteria:- Less than 18 years old.
- Major fetal anomalies
- Use of steroid medications in the past 2 weeks.
Data sourced from ClinicalTrials.gov (NCT01165775). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.